---
schema_version: "secwatch.filing_event.v1"
accession: "0000898432-23-000037"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T01:59:19.481549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iRadimed Q4 revenue $14.9M (+25% YoY); declares special $1.05 dividend; FY23 guidance $61-63M

## Summary
- Q4 2022 revenue $14.9M (vs $11.9M Q4 2021); GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.32.
- Full-year 2022 revenue $53.3M (vs $41.8M FY2021); GAAP EPS $1.02; non-GAAP EPS $1.10.
- Board declared special cash dividend of $1.05/share, payable Feb 21, 2023 to holders of record Feb 13, 2023.
- FY 2023 guidance: revenue $61-63M, GAAP EPS $1.10-1.20, non-GAAP EPS $1.23-1.34; Q1 2023 revenue $14.6-14.9M.
- Cash and equivalents $57.9M, no debt; gross margin 77.4% for full year 2022 (up from 76.6%).

## SEC filing metadata
- accession: 0000898432-23-000037
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000898432-23-000037
- JSON: https://secwatch.observer/filing/0000898432-23-000037.json
- Plain text: https://secwatch.observer/filing/0000898432-23-000037.txt

## Key facts
- Earnings Releases
  IRADIMED CORP reported the twelve months ended December 31, 2022 results: revenue $53.3 million, net income $12.8 million, EPS $1.02 per diluted share. Guidance initiated.
  - Period: the twelve months ended December 31, 2022
  - Revenue: $53.3 million
  - Net income: $12.8 million
  - EPS: $1.02 per diluted share
  - Guidance: initiated
  - Result: reported results
  source text: For the twelve months ended December 31, 2022, the Company reported revenue of $53.3 million compared to $41.8 million for the same period in 2021. Net income was $12.8 million, or $1.02 per diluted share, compared to $9.3 million, or $0.74 per diluted share, for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm
- Earnings Releases
  IRADIMED CORP reported full year 2023 results: revenue $61 million to $63 million, EPS $1.10 to $1.20 per diluted share (GAAP). Guidance initiated.
  - Period: full year 2023
  - Revenue: $61 million to $63 million
  - EPS: $1.10 to $1.20 per diluted share (GAAP)
  - Guidance: initiated
  - Result: guidance update
  source text: For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm
- Earnings Releases
  IRADIMED CORP reported first quarter of 2023 results: revenue $14.6 million to $14.9 million, EPS $0.23 to $0.25 per diluted share (GAAP). Guidance initiated.
  - Period: first quarter of 2023
  - Revenue: $14.6 million to $14.9 million
  - EPS: $0.23 to $0.25 per diluted share (GAAP)
  - Guidance: initiated
  - Result: guidance update
  source text: For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm
- Earnings Releases
  IRADIMED CORP reported the fourth quarter ended December 31, 2022 results: revenue $14.9 million, net income $3.7 million, EPS $0.29 per diluted share. Guidance initiated.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $14.9 million
  - Net income: $3.7 million
  - EPS: $0.29 per diluted share
  - Guidance: initiated
  - Result: reported results
  source text: For the fourth quarter ended December 31, 2022, the Company reported revenue of $14.9 million compared to $11.9 million for the fourth quarter of 2021. Net income was $3.7 million, or $0.29 per diluted share, compared to $3.9 million, or $0.31 per diluted share, for the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.